MedTrace Logo

Bioequivalence Study of Metoprolol Succinate ER Tablets, 200 mg Under Fasting Conditions

NCT01673997 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2012-09-25

No results posted yet for this study

Summary

The purpose of this study is to monitor adverse events, safety and tolerance Metoprolol Succinate Extended-Release Tablets 200 mg under fasting conditions

Conditions

  • Healthy

Interventions

DRUG

Metoprolol Succinate

Metoprolol Succinate ER Tablets 200 mg

Sponsors & Collaborators

  • Dr. Reddy's Laboratories Limited

    lead INDUSTRY

Principal Investigators

  • Dr. P. Vijaya Lakshmi, Clinical Investigator · Bioserve Clinical Research Private Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • India

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01673997 on ClinicalTrials.gov